发布求助
文献互助 智能选刊 最新文献

International journal of clinical practice. Supplement最新文献

筛选
英文 中文
The metabolic syndrome in women: implications for therapy. 女性代谢综合征:对治疗的影响。
International journal of clinical practice. Supplement Pub Date : 2004-03-01
Giuseppe M C Rosano, Cristiana Vitale, Antonello Silvestri, Massimo Fini
{"title":"The metabolic syndrome in women: implications for therapy.","authors":"Giuseppe M C Rosano,&nbsp;Cristiana Vitale,&nbsp;Antonello Silvestri,&nbsp;Massimo Fini","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>It is becoming increasingly clear that hypertension and metabolic risk factors in women are inter-related and often share underlying causes. Menopause acts explicitly as a risk factor by reducing the direct beneficial effect of ovarian hormones upon cardiovascular functions and indirectly by negatively influencing other risk factors for coronary artery disease--i.e. hyperinsulinaemia, blood cholesterol, blood pressure, coagulation etc. Adverse changes in one factor may induce adverse changes in a variety of other risk factors and it is important to consider co-ordinated changes when evaluating these patients rather than attempt to isolate independent factors. Similarly with treatment, the prevalence of metabolic syndrome in postmenopausal hypertensive women has important implications and some antihypertensive drugs may worsen the already altered metabolic profile of these patients while others may be beneficial. Centrally-acting sympatholytic agents, e.g. moxonidine, are therefore important to consider in hypertensive postmenopausal women who experience other symptoms of metabolic syndrome.</p>","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24495590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of postmenopausal hypertension. 绝经后高血压的流行病学。
International journal of clinical practice. Supplement Pub Date : 2004-03-01
Lena Sjöberg, Risto Kaaja, Jaakko Tuomilehto
{"title":"Epidemiology of postmenopausal hypertension.","authors":"Lena Sjöberg,&nbsp;Risto Kaaja,&nbsp;Jaakko Tuomilehto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hypertension is more common in younger men than women but this trend is inverted at approximately 60 years of age--thereafter hypertension is more common in women. Menopause's contribution to this phenomenon is complex. Oestrogen deficiency after menopause precipitates a number of factors and these have established the 'menopausal metabolic syndrome' as a concept in postmenopausal women. However, studies have indicated that changes in the prevalence of hypertension, and overall cardiovascular risk profiles in postmenopausal women, might be due to ageing and not oestrogen deficiency. Undoubtedly, there is a strong multicolinearity between the two phenomena. Furthermore, hormone replacement therapy (HRT) may reduce age-induced blood pressure increases, thus decreasing cardiovascular risks. However, recent results have questioned HRT's role in cardiovascular disease (CVD) prevention in postmenopausal women and trials have unequivocally shown that CVD risk in postmenopausal women with hypertension can be effectively reduced by common antihypertensive drugs.</p>","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24495081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basic research into the mechanisms responsible for postmenopausal hypertension. 绝经后高血压发病机制的基础研究。
International journal of clinical practice. Supplement Pub Date : 2004-03-01
Jane F Reckelhoff
{"title":"Basic research into the mechanisms responsible for postmenopausal hypertension.","authors":"Jane F Reckelhoff","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Women typically experience increased cardiovascular disease (CVD) following menopause. Major risk factors for CVD include hypertension and, after menopause, blood pressure increases in women. The mechanism(s) responsible for this increase are not determined. Changes in oestrogen/androgen ratios, possible activation of the renin-angiotensin system, and increases in endothelin and oxidative stress, are hallmarks in postmenopausal women. Obesity, type 2 diabetes and activation of the sympathetic nervous system may also play important roles. However, progress in clarifying the mechanisms responsible for postmenopausal hypertension has been hampered by lack of a suitable animal model. We have recently characterised the ageing female spontaneously hypertensive rat (SHR) as a model of postmenopausal hypertension, since this strain exhibits many of the humoral characteristics of postmenopausal women. This review discusses some of the mechanisms that could play a role in postmenopausal hypertension, as well as the characteristics of the ageing female SHR as a model.</p>","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24495082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. 选择性咪唑啉受体激动剂莫onidine治疗绝经后高血压。
International journal of clinical practice. Supplement Pub Date : 2004-03-01
Risto Kaaja, Karin Manhem, Jaakko Tuomilehto
{"title":"Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.","authors":"Risto Kaaja,&nbsp;Karin Manhem,&nbsp;Jaakko Tuomilehto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study compared the effects of two sympatholytic agents--one central (moxonidine) and one peripheral (atenolol)--on blood pressure and other metabolic syndrome factors in postmenopausal hypertensive women who were not taking hormone replacement therapy. Atenolol and moxonidine led to a statistically significant reduction in diastolic blood pressure of 9.5 mmHg and 5.5 mmHg, respectively. A clear rebound effect was observed in the atenolol patients whereas the moxonidine group exhibited a slightly further decrease in blood pressure. Moxonidine also caused a profound decrease in both mean plasma-glucose area under the curve (AUC) during oral glucose tolerance test (-0.96 mmol/L x H, NS) and mean plasma-insulin AUC (-6.15 mU/L x H). Therefore, moxonidine displayed a slightly less potent antihypertensive effect than atenolol in hypertensive postmenopausal women, but it demonstrated a better metabolic effect. To conclude, moxonidine could benefit hypertensive postmenopausal women who display other signs of metabolic syndrome.</p>","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24495591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statins: how far have we come? A review of rosuvastatin. 他汀类药物:我们已经走了多远?瑞舒伐他汀综述。
International journal of clinical practice. Supplement Pub Date : 2003-10-01
Anders Olsson
{"title":"Statins: how far have we come? A review of rosuvastatin.","authors":"Anders Olsson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24102516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction. Lipids, inflammation and CVD--understanding the basics to break the atherosclerosis cycle. 介绍。血脂、炎症和心血管疾病——了解打破动脉粥样硬化循环的基础知识。
International journal of clinical practice. Supplement Pub Date : 2003-10-01
Philip Barter
{"title":"Introduction. Lipids, inflammation and CVD--understanding the basics to break the atherosclerosis cycle.","authors":"Philip Barter","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24102514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statins: putting the benefit/risk into perspective. 他汀类药物:正确看待利弊。
International journal of clinical practice. Supplement Pub Date : 2003-10-01
James Shepherd
{"title":"Statins: putting the benefit/risk into perspective.","authors":"James Shepherd","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24102517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dyslipidaemia versus endothelial dysfunction: which is more important in the development of vascular disease? 血脂异常与内皮功能障碍:哪个在血管疾病的发展中更重要?
International journal of clinical practice. Supplement Pub Date : 2003-10-01
Ele Ferrannini, Jaakko Tuomilehto
{"title":"Dyslipidaemia versus endothelial dysfunction: which is more important in the development of vascular disease?","authors":"Ele Ferrannini,&nbsp;Jaakko Tuomilehto","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24102515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global cardiovascular risk assessment: improving strategies in patients at intermediate risk. 全球心血管风险评估:改善中等风险患者的策略
International journal of clinical practice. Supplement Pub Date : 2003-10-01
Wolfgang Koenig
{"title":"Global cardiovascular risk assessment: improving strategies in patients at intermediate risk.","authors":"Wolfgang Koenig","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24102518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A general overview of the use of ibuprofen in paediatrics. 布洛芬在儿科的使用概况。
International journal of clinical practice. Supplement Pub Date : 2003-04-01
Elisabeth Autret-Leca
{"title":"A general overview of the use of ibuprofen in paediatrics.","authors":"Elisabeth Autret-Leca","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ibuprofen is prescribed for children for the treatment of acute pain and fever, and for juvenile idiopathic arthritis. The pharmacokinetic characteristics of ibuprofen in children are similar to those in adults and the relationship between dose and response is linear over the range 5-10 mg/kg. Clinical trials of ibuprofen have shown the effective dose range to be 7.5-10 mg/kg. The maximum reduction in temperature occurs 3-4 hours after administration. In comparative clinical trials, ibuprofen has been shown to be equally as effective as or more effective than paracetamol as an analgesic and antipyretic and to have a longer duration of action; it is also as effective as aspirin. The adverse effects of ibuprofen are similar to those of other non-steroidal anti-inflammatory drugs but clinical experience suggests that ibuprofen is better tolerated by children than adults and it is safer in overdose than paracetamol and aspirin.</p>","PeriodicalId":73436,"journal":{"name":"International journal of clinical practice. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2003-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22364806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信